Sandoz Tests Direct‑to‑Consumer Sales With Omnitrope Growth Hormone Biosimilar

Sandoz is testing a direct-to-consumer (DTC) sales model for Omnitrope, its growth hormone biosimilar used to treat growth‑hormone‑related disorders in children and adults. The move marks one of the first major generiсs and biosimilars companies to experiment with selling biologic products directly to patients, rather than relying solely on traditional pharmacy or hospital channels. This DTC initiative is seen as a potential precursor to broader direct‑to‑patient strategies for Sandoz’s pipeline of generic and biosimilar therapies, including anticipated GLP‑1 offerings such as generic liraglutide once they receive regulatory approvals.